{"id":774744,"title":"Cost effectiveness of a 21-valent pneumococcal conjugate vaccine in adults, CCDR 51(2/3) - Canada.ca","sourceCode":"phac","sourceName":"Public Health Agency of Canada","language":"en","captureDate":"2026-03-07","captureTimestamp":"2026-03-07T15:18:31.093000+00:00","jobId":7,"originalUrl":"https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2025-51/issue-2-3-february-march-2025/cost-effectiveness-21-valent-pneumococcal-conjugate-vaccine-adults.html","snippet":"Cost effectiveness of a 21-valent pneumococcal conjugate vaccine in adults Download this article as a PDF (715 KB) Published by: The Public Health Agency of Canada Issue: Volume 51-2/3, February/March 2025: Health Economics in Public Health Date published: February 2025 ISSN:…","rawSnapshotUrl":"/api/snapshots/raw/774744","browseUrl":"https://replay.healtharchive.ca/job-7/20260307151831/https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2025-51/issue-2-3-february-march-2025/cost-effectiveness-21-valent-pneumococcal-conjugate-vaccine-adults.html#ha_snapshot=774744","mimeType":"text/html","statusCode":200,"captureBackend":"playwright_warc","captureFidelity":"fallback"}